Hidden Harbor Capital Partners, together with other PE funds and international financial institutions, recently acquired Dayco, LLC, a 115-year-old world leader in engine drive systems and aftermarket services. Grandall served as the PRC counsel to Hidden Harbor, with Mr. Kevin Qian, General Counsel of International Development & Foreign Affairs, leading the Grandall team.
On 20 January 2023, the reorganization project of Wuxi Zhenhua Auto Parts Co., Ltd. (605319.SH, “Wuxi Zhenhua”) was passed and approved by China Securities Regulatory Commission.
On 16 January 2023, Beauty Farm Medical and Health Industry Inc. (2373.HK, “Beauty Farm”), a leading beaty and health management service company in China, was listed on the mainboard of HKEx. The company offered 40,536,500 shares globally at the issue price of HKD 19.32 with oversubscription by approximately 21.12 times in the HK public offering and 4.7 times in the international offering, and the maximum opening gain was over 70% on the first day.
Recently, Grandall Changsha Office advised Pengze County Urban Development Construction Group Co., Ltd. (“Pengze Construction Group”) in its issue of senior unsecured credit enhancement bonds with a maturity of 35 months and denominated in USD under Regulation S to raise funds for Pengze County rural habitat environment comprehensive improvement project and to supplement working capital. The bonds were unrated, with standby L/C provided by Jiujiang Bank Co., Ltd., and closed on 23 December 2022.
On 31 October 2022, Shanghai Sanrise Industries & Development Co., Ltd. (“Sanrise”) signed the 100% equity transaction with IMCD China, a subsidiary of IMCD N.V. IMCD has acquired 70% of equities of Sanrise, and the remaining 30% will be acquired in 2025. The founder of Sanrise will continue to lead the company after the first acquisition. Grandall Shanghai Office has acted as Sanrise's legal advisor with LI Qiang (managing partner of Shanghai Office), HUANG Chao and DONG Liang (partners of Shanghai Office) and other lawyers serving the case.
On 12 October 2022, the application filed by Beijing Sunho Pharmaceutical Co., Ltd. (430017.OC, “Beijing Sunho”) for its public offering and listing on Beijing Stock Exchange was passed and approved by the Listing Committee of Beijing Stock Exchange.
Recently Beijing Jingneng Clean Energy Co., Ltd. (00579.HK, “Jingneng”) has completed its cross-border equity swap project, and Grandall Beijing provided legal services in Jingneng’ swap of its equity in Beijing Jingneng Power Co., Ltd. (600578.SH), its parent company, with Beijing Energy Group Co., Ltd., a company directly under Beijing State-owned Assets Supervision and Administration Commission, for assets thereof. The total amount of the project is approximately RMB 4 billion.
In January 2022, Blogis Holding Co., Ltd. (“Blogis”) signed the agreement for acquisition of 100% equity in Hangzhou Suneng Industrial Co., Ltd. and successfully completed the transaction with a total consideration of hundreds of millions of RMB. Grandall Suzhou Office provided legal services for this acquisition, including legal due diligence, transaction structure design, draft and review of transaction documents and commercial negotiation.
On 27 September 2022, Hui Lyu Ecological Technology Groups Co., Ltd. (001267.SZ, “Hui Lyu”) successfully completed the non-public offering, and Grandall Wuhan Office provided legal services in this project.
Recently, Air China Limited (“Air China”) and Rolls-Royce Limited (“Rolls-Royce”) announced the formation of a joint venture company, namely, Beijing Aero Engine Services Company Limited (“BAESL”), engaging in civil aviation engine maintenance in Beijing. Having passed the antitrust review, BAESL is registered in the Beijing Capital International Airport Economic Zone. Grandall Beijing Office has been retained as Air China's legal advisor with Mr. Zhe JIN, Ms. Xintian HU, Ms. Xiaoyi FENG and Ms. Lingyan PEI as key lawyers serving the case.
On 8 July 2022, Rainmed Medical Limited (2297.HK) successfully made its initial public offering and was listed on the Mainboard of Hong Kong Stock Exchange with a market value of HKD 7,285 million at the time of listing based upon the issue price (regardless of over-allotment option).
